Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Metastatic colorectal cancer remains a serious public health concern, marked by tumor spread beyond the colon or rectum to distant organs. Nearly 23% of US colorectal cancer patients are diagnosed at the distant stage, where five-year survival remains below 20%. Rising incidence among younger adults is also increasing the need for earlier diagnosis and more effective treatment options. The metastatic colorectal cancer pipeline analysis by Expert Market Research reviews emerging therapies, clinical trials, and key developments shaping future patient care.
-
Major companies involved in the metastatic colorectal cancer pipeline analysis include AbbVie, Eli Lilly and Company, and others.
-
Leading drugs currently in the pipeline include INCA33890, LYL273, and others.
-
The pipeline growth is being driven by wider molecular profiling for BRAF, KRAS, HER2, MSI-H, and NTRK alterations. These biomarkers enable smaller, mutation-specific trials, support faster patient selection, and encourage combination strategies that can overcome resistance to chemotherapy, anti-EGFR therapy, and earlier targeted treatments more effectively.
Report Coverage
The Metastatic Colorectal Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into metastatic colorectal cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for metastatic colorectal cancer. The metastatic colorectal cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The metastatic colorectal cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with metastatic colorectal cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to metastatic colorectal cancer.
Read more about this report - Request a Free Sample
Metastatic Colorectal Cancer Pipeline Outlook
The metastatic colorectal cancer pipeline is shifting toward biomarker-led treatments and earlier use of targeted combinations. In February 2026, the FDA granted traditional approval to encorafenib with cetuximab and fluorouracil-based chemotherapy for BRAF V600E-mutated disease. Phase 3 programs are also assessing new antibody-drug conjugates and combinations for previously treated patients and selected first-line populations. Future progress will depend on stronger survival results, improved safety, wider molecular testing, and therapies addressing KRAS mutations, HER2-positive tumors, and treatment-resistant disease across later-line settings.
Metastatic Colorectal Cancer Epidemiology
Metastatic colorectal cancer remains a major clinical burden. In the United States, 158,850 colorectal cancer cases and 55,230 deaths are expected in 2026. SEER data show that 23% of patients are diagnosed with distant-stage disease, with a five-year relative survival rate of 16.9%. Among adults younger than 50, 27% present with distant-stage cancer. Incidence of regional and distant disease among adults aged 50–64 increased by roughly 1.1%-1.3% annually during 2013-2022, highlighting a growing younger-patient burden and need for earlier detection.
Metastatic Colorectal Cancer – Pipeline Therapeutic Assessment
This section of the report covers the analysis of metastatic colorectal cancer drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The metastatic colorectal cancer pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Cell Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Metastatic Colorectal Cancer Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total metastatic colorectal cancer clinical trials. Early Phase I (2.03%), Phase I (36.72%), Phase II (48.52%), Phase III (11.44%), and Phase IV (1.11%). The report provides comprehensive insights into the distribution of drug candidates across different clinical development stages, highlighting the maturity and progression of the metastatic colorectal cancer pipeline.
Metastatic Colorectal Cancer Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the metastatic colorectal cancer pipeline analysis include small molecules, monoclonal antibodies, and cell therapies. The metastatic colorectal cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for metastatic colorectal cancer. In April 2025, the FDA approved nivolumab (Opdivo) with ipilimumab (Yervoy) for patients aged 12 years and older with unresectable or metastatic MSI-H or dMMR colorectal cancer.
Metastatic Colorectal Cancer Clinical Trials – Key Players
The EMR report for the metastatic colorectal cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed metastatic colorectal cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in metastatic colorectal cancer clinical trials:
- Novartis Pharmaceuticals
- Hoffmann-La Roche
- Janssen Research & Development, LLC
- Hansoh BioMedical R&D Company
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Hefei TG ImmunoPharma Co., Ltd.
- Erasca, Inc.
- Biogenea Pharmaceuticals Ltd.
- Philogen S.p.A.
- AbbVie
- Eli Lilly and Company
- Kivu Bioscience Inc.
Metastatic Colorectal Cancer – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for metastatic colorectal cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of metastatic colorectal cancer drug candidates.
Drug: INCA33890
INCA33890 is a monoclonal antibody developed by Incyte Corporation for the treatment of metastatic colorectal cancer. The investigational therapy targets immune-regulatory pathways within the tumor microenvironment to enhance antitumor immune responses and improve the efficacy of immunotherapy in advanced disease. The ongoing clinical study is expected to be completed in 2028. Incyte is a global biopharmaceutical company recognized for developing innovative oncology and immunology therapies with a strong portfolio of targeted and immune-based treatments.
Drug: LYL273
LYL273 is a cell therapy candidate being developed by Lyell Immunopharma, Inc. for metastatic colorectal cancer. It utilizes genetically engineered T cells designed to improve persistence, resist T-cell exhaustion, and maintain potent antitumor activity against metastatic solid tumors. The ongoing clinical trial is expected to be completed in 2029. Lyell Immunopharma specializes in next-generation cell therapies, leveraging advanced genetic engineering technologies to develop durable immunotherapies for patients with difficult-to-treat solid cancers.
Biological: SOT109
SOT109 is a biological cell therapy being developed by SOTIO Biotech for the treatment of metastatic colorectal cancer. The investigational therapy is designed to stimulate targeted immune responses against tumor-associated antigens, promoting immune-mediated destruction of metastatic cancer cells while enhancing therapeutic specificity. The ongoing clinical study is expected to be completed in 2028. SOTIO Biotech is an international biotechnology company focused on developing innovative immuno-oncology therapies, including cellular immunotherapies and antibody-based treatments for solid tumors.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Metastatic Colorectal Cancer Pipeline Insight Report
- Which companies/institutions are leading the metastatic colorectal cancer drug development?
- Which company is leading the metastatic colorectal cancer pipeline development activities?
- What is the current metastatic colorectal cancer commercial assessment?
- What are the opportunities and challenges present in the metastatic colorectal cancer pipeline landscape?
- What is the efficacy and safety profile of metastatic colorectal cancer pipeline drugs?
- Which company is conducting major trials for metastatic colorectal cancer drugs?
- Which companies/institutions are involved in metastatic colorectal cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in metastatic colorectal cancer?
Reasons To Buy This Report
The Metastatic Colorectal Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for metastatic colorectal cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into metastatic colorectal cancer collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Colorectal Cancer Therapeutics Market
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
